Toshihiro Kobayashi

Toshihiro Kobayashi

Auto-generated profile, based on publicly available information

Toshihiro Kobayashi

Koshien University

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2007 in Cell Metabolism
Verified
Journal Article
Closed access
STSawako Tatsumi
Sawako Tatsumi
KIKiyoaki Ishii
Kiyoaki Ishii
NANorio Amizuka
Norio Amizuka
MLMinqi Li
Minqi Li
TKToshihiro Kobayashi
Toshihiro Kobayashi
KIKyoji Ikeda
Kyoji Ikeda

25 August 2005 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
DWDaisuke Watanabe
Daisuke Watanabe
KSKiyoshi Suzuma
Kiyoshi Suzuma
SMShigeyuki Matsui
Shigeyuki Matsui
MKMasafumi Kurimoto
Masafumi Kurimoto
JKJunichi Kiryu
Junichi Kiryu
HTHitoshi Takagi
Hitoshi Takagi
Although vascular endothelial growth factor (VEGF) is a primary mediator of retinal angiogenesis, VEGF inhibition alone is insufficient to prevent retinal neovascularization. Hence, it is postulated that there are other potent ischemia-induced angiogenic factors. Erythropoietin possesses angiogenic activity, but its potential role in ocular angiogenesis is not established. We measured both erythropoietin and VEGF levels in the vitreous fluid of 144 patients with the use of radioimmunoassay and enzyme-linked immunosorbent assay. Vitreous proliferative potential was measured according to the growth of retinal endothelial cells in vitro and with soluble erythropoietin receptor. In addition, a murine model of ischemia-induced retinal neovascularization was used to evaluate erythropoietin expression and regulation in vivo. The median vitreous erythropoietin level in 73 patients with proliferative diabetic retinopathy was significantly higher than that in 71 patients without diabetes (464.0 vs. 36.5 mIU per milliliter, P<0.001). The median VEGF level in patients with retinopathy was also significantly higher than that in patients without diabetes (345.0 vs. 3.9 pg per milliliter, P<0.001). Multivariate logistic-regression analyses indicated that erythropoietin and VEGF were independently associated with proliferative diabetic retinopathy and that erythropoietin was more strongly associated with the presence of proliferative diabetic retinopathy than was VEGF. Erythropoietin and VEGF gene-expression levels are up-regulated in the murine ischemic retina, and the blockade of erythropoietin inhibits retinal neovascularization in vivo and endothelial-cell proliferation in the vitreous of patients with diabetic retinopathy in vitro. Our data suggest that erythropoietin is a potent ischemia-induced angiogenic factor that acts independently of VEGF during retinal angiogenesis in proliferative diabetic retinopathy.

1 December 2000 in American Journal of Physiology-Endocrinology and Metabolism
Verified
Journal Article
Closed access
PDF file
MCMariko Chikuma
Mariko Chikuma
SMSeiji Masuda
Seiji Masuda
TKToshihiro Kobayashi
Toshihiro Kobayashi
MNMasaya Nagao
Masaya Nagao
RSRyuzo Sasaki
Ryuzo Sasaki
Erythropoietin (Epo) produced by the kidney regulates erythropoiesis. Recent evidence suggests that Epo in the cerebrum prevents neuron death and Epo in the uterus induces estrogen (E2)-dependent uterine angiogenesis. To elucidate how Epo expression is regulated in these tissues, ovariectomized mice were given E2and/or exposed to hypoxia, and the temporal patterns of Epo mRNA levels were examined. Epo mRNA levels in the kidney and cerebrum were elevated markedly within 4 h after exposure to hypoxia. Although the elevated level of Epo mRNA in the kidney decreased markedly within 8 h despite continuous hypoxia, the high level in the cerebrum was sustained for ≥24 h, indicating that downregulation operates in the kidney but not in the brain. E2transiently induced Epo mRNA in the uterus but not in the kidney and cerebrum. Interestingly, the uterine Epo mRNA was hypoxia inducible only in the presence of E2. Thus Epo expression appears to be regulated in a tissue-specific manner, endorsing the tissue-specific functions of Epo.

1 June 2000 in American Journal of Physiology-Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
SMSeiji Masuda
Seiji Masuda
TKToshihiro Kobayashi
Toshihiro Kobayashi
MCMariko Chikuma
Mariko Chikuma
MNMasaya Nagao
Masaya Nagao
RSRyuzo Sasaki
Ryuzo Sasaki
Previously, we showed that erythropoietin (Epo) is produced in the mouse uterus, where Epo is indispensable for estrogen (E2)-dependent angiogenesis. Expression of uterine Epo mRNA is stimulated by E2and hypoxia. The hypoxic induction requires the presence of E2. In the present study, we examined other female reproductive organs in the mouse with respect to Epo mRNA expression and its stimuli (E2and hypoxia)-induced changes. Although Epo mRNA expression was seen in the ovary and oviduct, the E2-induced stimulation of Epo mRNA was found only in the oviduct. The E2-induced stimulation in the oviduct was transient and rapidly downregulated. Epo mRNA expression in the oviduct was hypoxia inducible, in both the presence and the absence of E2. E2-dependent production of Epo and its mRNA expression were also found by use of cultured oviducts. The E2action is probably mediated through the E2receptor, and de novo protein synthesis is not required for E2induction of Epo mRNA. In the oviduct, the ampulla and isthmus regions produce Epo.

1 August 2002 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
TKToshihiro Kobayashi
Toshihiro Kobayashi
HYHaruko Yanase
Haruko Yanase
TIToshihiko Iwanaga
Toshihiko Iwanaga
RSRyuzo Sasaki
Ryuzo Sasaki
MNMasaya Nagao
Masaya Nagao

1 March 2014 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
TKToshihiro Kobayashi
Toshihiro Kobayashi
TYTatsunari Yoshida
Tatsunari Yoshida
TFTatsuya Fujisawa
Tatsuya Fujisawa
YMYuriko Matsumura
Yuriko Matsumura
TOToshihiko Ozawa
Toshihiko Ozawa
NTNoriaki Tanaka
Noriaki Tanaka